🔗 Share this article

While America proceeds with sweeping adjustments to its vaccination recommendations, one figure appears somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and public health researcher who rose to prominence by casting doubt on coronavirus vaccinations during the global health crisis and has concentrated on alleged deaths after COVID-19 immunization in her short position at the FDA.

Scheduled Shifts to Pediatric Vaccine Program

Health officials had intended to unveil radical changes to the childhood vaccine schedule earlier this month, aligning the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US at odds with a large portion of the global community with no evidence for public health gain. The announcement has been pushed back until the next year.

In place of the top vaccines chief, Dr. Høeg is set to present at the gathering. She was recently named temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this calendar year.

A New Direction at the FDA

The acting appointment may indicate a closer partnership between the drug and biologics centers as Høeg and Dr. Prasad consolidate power at the agency – and it points to a renewed priority upon reevaluating already-approved vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing certain pediatric vaccine recommendations in the US to become more like the Danish model, a nation with universal health coverage and a number of inhabitants about the size of Wisconsin’s.

To date public appearances, she has continued to focus on immunizations – traditionally the domain of Dr. Prasad, chief of the FDA’s vaccine center – as opposed to drug regulation.

Concerns Over Qualifications

Høeg has no apparent track record in medication creation, regulation or leadership, which has been typical for former heads of the Center for Biologics Evaluation and Research. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for overseeing the pharmaceutical oversight division, said a neurologist and psychiatrist. “She lacks experience running a randomized controlled trial. She is not versed in managing a sizeable institution. She is not an expert in industry regulation.”

Previous heads of CBER would “understand regulatory frameworks and the science of drug development”, commented a former acting FDA commissioner. “Frankly, she has not acquired the sort of resume that prior appointees who ran the center have had.”

The drug center has an vast workload at the FDA, the former commissioner stated.

“Many people just zeroes in on the novel medication approvals, but the generic program authorizes a multitude of off-brand pharmaceuticals. There’s a biosimilars program, OTC medication office and more, and all of those need to be looked after,” Dr. Woodcock noted. “The thing you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Furthermore, a significant administrative component to the role, which supervises more than 5,000 employees. “It’s a massive leadership role, if you perform it correctly,” Woodcock concluded.

Agency Reaction and Controversial Initiatives

Regarding inquiries about Høeg’s credentials and whether this appointment represents increased cooperation among regulatory chiefs on immunizations, a representative stated that the “concerns stem from incorrect premises”.

“This background aligns with the responsibilities of her position,” the spokesperson explained, pointing to the period Høeg spent guiding the FDA commissioner on “pharmaceutical safety and regulatory science, including computational safety modeling and vaccine surveillance”.

As acting director, Høeg takes over the agency head's recently launched fast-track approval initiative, a contentious expedited drug-approval program that allegedly worried her preceding directors. “By what process are these therapies being selected for this voucher program? Who takes the choices?” Howard asked. “There is a lot of secrecy occurring at the FDA right now.”

In general, he remarked, “the agency seems to be moving towards laxer oversight of all drugs, aside from shots.”

Established Track Record on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if problematic, history, Howard have noted. She released a study using unconfirmed public submissions to estimate the frequency of heart inflammation after Covid immunization. She consulted for the Florida top health official Joseph Ladapo, who reportedly have altered data to imply COVID-19 vaccines are riskier than they are.

Among her “wish list” for the new federal leadership featured changing guidelines for new vaccines and halting “unnecessary” vaccines, she stated after the election on a online show. At the agency, Høeg has allegedly suggested preventing adolescent males from receiving Covid vaccinations.

“She’s an thorough true believer who commences with her conclusions and reverse-engineers to fit the data in a very deceptive, fraudulent manner,” Howard said.

Gaining Influence and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|